NVO Jan 2026 80.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 02:06PM EDT
Loading interactive chart…
- Bloomberg
Novo’s Ozempic Slashes Risk of Death in Kidney Disease Study
(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a constellation of disorders. Most Read from BloombergWhat the Trump Jury Saw as Evidence Against Him in 12 ImagesSingapore Air Changes Seatbelt Rules After Fatal TurbulenceSpaceX Weighs Plan to Sell Shares at $200 Billion ValuationThe Rise and Fall of Simon Sadler's Segantii, One of Asia's Most Successful Hedge Fu
- Zacks
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy
Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
- Zacks
Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
© 2024 Yahoo. All rights reserved.